EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Ribociclib plus Endocrine Therapy in Early Breast Cancer

Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas McAndrew, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, Peter A Fasching, John Crown, Aditya Bardia, Stephen Chia und 19 weitere

New England Journal of Medicine · 21.03.2024 · 390 (12) · 1080-1091

DOI: 10.1056/nejmoa2305488 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 21.03.2024. Verfasst von Dennis Slamon und 30 weiteren Autor:innen. Beteiligte Einrichtung: From the David Geffen School of Medicine at the University of California, Los Angeles (D. Slamon, N.M.); Republican Clinical Oncology Dispensary, Ufa…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Letrozole, Aromatase Inhibitors. Die Arbeit wurde bisher 430-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsLetrozoleAromatase InhibitorsFemaleHumansAminopyridinesPurinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneGoserelinAntineoplastic Agents, HormonalMale

Substanzen

AminopyridinesLetrozolePurinesErb-b2 Receptor Tyrosine KinasesAromatase InhibitorsReceptors, EstrogenReceptors, ProgesteroneGoserelinAntineoplastic Agents, Hormonalribociclib

Autor:innen und Institutionen

  • From the David Geffen School of Medicine at the University of California, Los Angeles (D. Slamon, N.M.); Republican Clinical Oncology Dispensary, Ufa (O.L.), and Moscow City Oncology Hospital No. 62, Moscow (D. Stroyako…

ORCID-Profile: Gabriel Hortobagyi

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C. S., Fasching, P. A., Crown, J., Bardia, A., Chia, S., Im, S. A., Ruiz-Borrego, M., Loi, S., Xu, B., Hurvitz, S., Barrios, C., Untch, M., …, & Hortobagyi, G. (2024). Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine, 390(12), 1080-1091. https://doi.org/10.1056/nejmoa2305488

Vancouver

Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine. 2024;390(12):1080-1091. doi:10.1056/nejmoa2305488

BibTeX
@article{Slamon2024,
  author = {Slamon, Dennis and Lipatov, Oleg and Nowecki, Zbigniew and McAndrew, Nicholas and Kukielka-Budny, Bozena and Stroyakovskiy, Daniil and Yardley, Denise A and Huang, Chiun-Sheng and Fasching, Peter A and Crown, John and Bardia, Aditya and Chia, Stephen and Im, Seock-Ah and Ruiz-Borrego, Manuel and Loi, Sherene and Xu, Binghe and Hurvitz, Sara and Barrios, Carlos and Untch, Michael and Moroose, Rebecca and Visco, Frances and Afenjar, Karen and Fresco, Rodrigo and Severin, Irene and Ji, Yan and Ghaznawi, Farhat and Li, Zheng and Zarate, Juan P and Chakravartty, Arunava and Taran, Tetiana and Hortobagyi, Gabriel},
  title = {Ribociclib plus Endocrine Therapy in Early Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {12},
  pages = {1080--1091},
  doi = {10.1056/nejmoa2305488}
}
Kostenlos starten →